Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 7, 2025, Soligenix, Inc. (SNGX) announced financial results for the third quarter of 2025 and provided a business update.</li><li>Recently, the Data Monitoring Committee (DMC) for the ongoing confirmatory Phase 3 clinical trial of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL) concluded that there were no safety concerns and that HyBryte has an acceptable safety profile consistent with the safety data from all previous clinical studies.</li><li>We anticipate an update on enrollment from the company in the fourth quarter of 2025 and a pre-specified blinded interim efficacy analysis in the first half of 2026.</li></ul>

On November 7, 2025, Soligenix, Inc. (SNGX) announced financial results for the third quarter of 2025 and provided a business update.Recently, the Data Monitoring Committee (DMC) for the ongoing confirmatory Phase 3 clinical trial of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL) concluded that there were no safety concerns and that HyBryte has an acceptable safety profile consistent with the safety data from all previous clinical studies.We anticipate an update on enrollment from the company in the fourth quarter of 2025 and a pre-specified blinded interim efficacy analysis in the first half of 2026.

SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL  Blinded Interim Efficacy Analysis in 1H26